Unicycive Therapeutics In... (UNCY)
| Bid | 3.65 |
| Market Cap | 66.05M |
| Revenue (ttm) | 568K |
| Net Income (ttm) | -31.5M |
| EPS (ttm) | -2.74 |
| PE Ratio (ttm) | -1.36 |
| Forward PE | 0.33 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 3.94 |
| Volume | 525,779 |
| Avg. Volume (20D) | 619,784 |
| Open | 3.85 |
| Previous Close | 3.85 |
| Day's Range | 3.72 - 3.96 |
| 52-Week Range | 3.40 - 11.00 |
| Beta | 1.86 |
| Ex-Dividend Date | n/a |
About UNCY
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for UNCY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription
8 hours ago · businesswire.com
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCYLOS ANGELES--(BUSINESS WIRE)--Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY.
1 month ago · businesswire.com
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES--(BUSINESS WIRE)---- $UNCY--UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
2 months ago · seekingalpha.com
Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, BuyingInitiating coverage on Unicycive Therapeutics, Inc. with a Buy rating and $6 price target, as the recent FDA CRL is manufacturing-related and resolvable. OLC's ultra-low pill burden and strong patient...
2 months ago · businesswire.com
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law FirmLOS ANGELES--(BUSINESS WIRE)---- $UNCY--UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.